AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Bogdanoff who wrote (511)	8/19/1997 12:41:00 PM
From: squetch	of 2173

David, I have only a little more to add on CNBC interview. CEO said Type I in all four endpoints was stat significant. In the glucose indication for Type I, the results were not as strong as we wanted. I am not positive he used wanted but believe it to be true. Most of the rest seemed to be explaining poor trial design. >>Also they made protocol adjustments in remaining four studies to control for insulin intake and to select on a subgroup of patients.<< Hopefully this will help the results, but I agree with you as it seems like bad science to my liberal arts mind. He also mentioned looking at subsets. This seems like it is an expensive fishing expedition. As told by a LGND shareholder...Chicken Little

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next